Immuno-Oncology Partnerships iOmx Therapeutics AG is a Munich-area immuno-oncology startup building a portfolio of next-generation immune-checkpoint therapies in preclinical and clinical development. The company has attracted internationally renowned investors, signaling openness to strategic collaborations and co-development with industry partners. The lead program OMX-0407 represents a potential entry point for partnership discussions with pharma players seeking innovation in immuno-oncology.

CDMO Manufacturing Needs As iOmx advances OMX-0407 toward IND-enabling studies, there is a clear need for GMP-grade API supply, process development, analytical development, and scalable formulation and fill-finish capabilities. This creates strong sales opportunities for contract development and manufacturing organizations that specialize in early-stage, high-value small molecules and can support regulatory documentation and quality systems.

Biomarker Analytics To accelerate trial timelines, iOmx could benefit from biomarker driven clinical development services, including immune profiling, companion diagnostics, translational analytics, and centralized data management for multi-site studies. Partners offering integrated CRO services in trial design, biomarker assays, and real-time data insights could win expansion opportunities across iOmx’s preclinical to clinical pipeline.

Licensing Opportunities With a first-in-class oral SIK3 inhibitor in its portfolio and backing from strategic investors, iOmx is positioned for licensing or co-development deals with larger biopharma players seeking novel approaches in immune modulation. Business development conversations could explore upfront licensing, milestone-driven collaborations, and joint development across international markets.

Leadership Signals Recent leadership appointments indicate a growing business development focus and readiness to engage external partners. Engaging with iOmx’s leadership and BD teams can help tailor partnership proposals around risk-sharing models, strategic alliances, and long-term collaborations aligned with their financing trajectory and growth plans.